Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab in pediatric solid tumors
NCT02677116Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of olaratumab in solid tumor (9 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Olaratumab Dose Limiting Toxicities. Started Aug 2016; status: completed.
02
Drugs
olaratumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02677116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677116.